Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company Drug

AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico

Fineline Cube Jul 25, 2023

Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...

R&D

Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population

Fineline Cube Jul 25, 2023

Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...

Company Deals

Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment

Fineline Cube Jul 25, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...

Company Deals

Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program

Fineline Cube Jul 25, 2023

Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...

Company Drug

Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial

Fineline Cube Jul 25, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...

Company Drug

Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment

Fineline Cube Jul 25, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Company Policy / Regulatory

Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments

Fineline Cube Jul 25, 2023

The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...

Company Drug

Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review

Fineline Cube Jul 25, 2023

US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development

Fineline Cube Jul 25, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...

Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Policy / Regulatory

NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update

Fineline Cube Jul 24, 2023

The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...

Company Deals

Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy

Fineline Cube Jul 24, 2023

Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...

Company Drug

BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment

Fineline Cube Jul 24, 2023

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...

Company Drug

CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032

Fineline Cube Jul 24, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...

Company Deals Drug

Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program

Fineline Cube Jul 24, 2023

Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...

Legal / IP Policy / Regulatory

National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector

Fineline Cube Jul 24, 2023

The emergency response department of the National Health Commission (NHC) has released a notification signaling...

Company

FDA Assures No Disruption to US Drug Supply Chain After Pfizer Warehouse Tornado

Fineline Cube Jul 24, 2023

The US Food and Drug Administration (FDA) has issued a statement this week, ruling out...

Company Deals

Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies

Fineline Cube Jul 21, 2023

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...

Posts pagination

1 … 500 501 502 … 667

Recent updates

  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
  • BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
  • China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases
  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.